Infectious disease: Genomics decodes drug action

Fairlamb, Alan H.
February 2012
Nature;2/9/2012, Vol. 482 Issue 7384, p167
Academic Journal
The article presents a genome-wide study that uses RNA interference in providing valuable insight on the drugs used to treat African trypanosomiasis or sleeping sickness caused by the single-celled parasite Trypanosoma brucei gambiense and T. b. rhodesiense. It mentions that among the drugs used include suramin and melarsoprol and offers the biological pathway of such drugs. It states that the existing antitrypanosome drugs are typically given by injection.


Related Articles

  • Chemotherapeutic Strategies Against Trypanosoma brucei: Drug Targets vs. Drug Targeting. L�scher, A.; de Koning, H. P.; M�ser, P. // Current Pharmaceutical Design;Feb2007, Vol. 13 Issue 6, p555 

    Trypanosoma brucei rhodesiense and T. b. gambiense are the causative agents of sleeping sickness, a fatal disease that affects 36 countries in sub-Saharan Africa. Nevertheless, only a handful of clinically useful drugs are available. These drugs suffer from severe side-effects. The situation is...

  • Human African trypanosomiasis in endemic populations and travellers. Blum, J.; Neumayr, A.; Hatz, C. // European Journal of Clinical Microbiology & Infectious Diseases;Jun2012, Vol. 31 Issue 6, p905 

    Human African trypanosomiasis (HAT) or sleeping sickness is caused by the protozoan parasites Trypanosoma brucei (T.b.) gambiense (West African form) and T.b. rhodesiense (East African form) that are transmitted by the bite of the tsetse fly, Glossina spp.. Whereas most patients in endemic...

  • African Trypanosomiasis Gambiense, Italy. Bisoffi, Zeno; Beltrame, Anna; Monteiro, Geraldo; Arzese, Alessandra; Marocco, Stefania; Rorato, Giada; Anselmi, Mariella; Viale, Pierluigi // Emerging Infectious Diseases;Nov2005, Vol. 11 Issue 11, p1745 

    African trypanosomiasis caused by Trypanosoma brucei gambiense has not been reported in Italy. We report 2 cases diagnosed in the summer of 2004. Theses cases suggest an increased risk for expatriates working in trypanosomiasis- endemic countries. Travel medicine clinics should be increasingly...

  • Protein phosphatase 5 is required for Hsp90 function during proteotoxic stresses in Trypanosoma brucei. Candace Jones; Sedrick Anderson; Ujjal Singha; Minu Chaudhuri // Parasitology Research;Apr2008, Vol. 102 Issue 5, p835 

    Abstract   Trypanosoma brucei, a parasitic protozoan that causes African trypanosomiasis in human and domestic animals, adapt in various environments during their digenetic life cycle. In this study, we found that Hsp90 is crucial for the survival of this parasite. Inhibition of Hsp90...

  • Cerebrospinal Fluid Neopterin as Marker of the Meningo-Encephalitic Stage of Trypanosoma brucei gambiense Sleeping Sickness. Tiberti, Natalia; Hainard, Alexandre; Lejon, Veerle; Courtioux, Bertrand; Matovu, Enock; Enyaru, John Charles; Robin, Xavier; Turck, Natacha; Kristensson, Krister; Ngoyi, Dieudonné Mumba; Vatunga, Gedeão M. L.; Krishna, Sanjeev; Büscher, Philippe; Bisser, Sylvie; Ndung'u, Joseph Mathu; Sanchez, Jean-Charles // PLoS ONE;Jul2012, Vol. 7 Issue 7, p1 

    Background: Sleeping sickness, or human African trypanosomiasis (HAT), is a protozoan disease that affects rural communities in sub-Saharan Africa. Determination of the disease stage, essential for correct treatment, represents a key issue in the management of patients. In the present study we...

  • Gambiense sleeping sickness: re-emerging and soon untreatable? Van Nieuwenhove, Simon // Bulletin of the World Health Organization;2000, Vol. 78 Issue 11, p1283 

    Editorial. Comments on the return of sleeping sickness caused by Trypanosoma brucei gambiense. Deterioration and disruption of control activities; Problems on the implementation of active case detection and successful treatment; Gap between scientific progress and the implementation of...

  • Trypanocidal activity of salinomycin is due to sodium influx followed by cell swelling. Steverding, Dietmar; Sexton, Darren W. // Parasites & Vectors;2013, Vol. 6 Issue 1, Special section p1 

    Background: The few currently available drugs for treatment of African trypanosomiasis are outdated and show problems with toxicity and resistance. Hence, there is an urgent need for the discovery and development of new anti-trypanosomal agents. Findings: In this study, the ionophorous...

  • The risk factors for relapse among patients with African trypanosomiasis in Daloa, Cote d'Ivoire. Cross, Pamela; Doua, Felix; Jaffar, Shabbar // Tropical Doctor;Apr2006, Vol. 36 Issue 2, p90 

    We describe rates of follow-up and the risk factors for relapse in a cohort of adult patients treated for Trypanosoma brucei gambiense African trypanosomiasis. 812 patients were discharged from hospital between 6 January 1983 and 16 January 1992. The numbers who did not attend a scheduled...

  • Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib.  // Parasites & Vectors;2009, Vol. 2 Issue 1, p29 

    The article presents a report on the in vitro activity of the proteasome inhibitor and anti-cancer drug bortezomib against bloodstream forms of Trypanosoma brucei. To reduce the growth rate by 50% and to kill all trypanosomes were 3.3 nM and 10 nM, respectively, it requires the concentrations of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics